The world ovarian cancer coalition every woman study: Identifying global and local challenges, and the opportunities to improve survival and quality of life for women no matter where they live

Reid, Frances; Jones, Ansgar

doi:10.1016/j.ygyno.2019.04.094

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usage of tobacco in the studies conducted in 2009 shows that they are interlinked with the cause of developing cancer, but previously in many studies this was not understood and this was not the root cause for ovarian cancer, the mucinous ovarian cancer was included in the World Organization for Research on Cancer [24][25][26][27]. The research on cancer transmission focuses on acquiring data on womens smoking habits have found that there is a connection between smoking habits and ovarian cancer as ovarian cancer is further caused due to smoking habits in women [28].…”

Section: Based On Smoking Habitsmentioning

confidence: 99%

Untitled

2023

J. Med. Chem. Sci.

View full text Add to dashboard Cite

The present study is an initiative to understand various related factors associated with ovarian cancer among millennials in India. The spark behind the present study after visiting various cancer patients in the locality motivated the author to work on the present study. In this regard, 12 hospitals approached and were able to collect some substantial data from the patients. Nine hypotheses were considered which were developed after the literature reviews. The results revealed that having children, having a mother with an ovarian cancer history, having a sister having ovarian cancer history, being obese, having late sleeping habits, and with IVF have a significant association with ovarian cancer and diabetics, smoking habits, and contraceptive pills do not have any direct association with ovarian cancer as opined by the participants K E Y W O R D S Ovarian Cancer Millennials Family HistoryIn vitro fertilization (IVF)

show abstract

Section: Based On Smoking Habitsmentioning

confidence: 99%

Untitled

2023

J. Med. Chem. Sci.

View full text Add to dashboard Cite

show abstract

“…Moreover, as per World Ovarian Cancer Coalition, future mortality prediction is pessimistic, with incidence set to rise by 47% by 2040. This prognosis regards particularly low- and middle-income countries [ 2 ]. Is is due to the expected increase in the women population over 60 years of age, i.e.…”

Section: Introductionmentioning

confidence: 99%

Angiotensin-converting enzyme inhibitors for ovarian cancer? — a new adjuvant option or a silent trap

Regulska,

Michalak,

Kolenda

et al. 2023

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background Ovarian cancer is a huge therapeutic and financial problem for which approved treatments have already achieved their limit of efficiency. A cost-effective strategy to extend therapeutic options in this malignancy is drug repurposing aimed at overcoming chemoresistance. Here, angiotensin-converting enzyme inhibitors (ACE-I) are worth considering. Materials and methods We searched literature for publications supporting the idea of adjuvant application of ACE-Is in ovarian malignancy. Then, we searched The Cancer Genome Atlas databases for relevant alternations of gene expression patterns. We also performed in silico structure-activity relationship evaluation for predicting ACE-Is’ cytotoxicity against ovarian cancer cell lines. Finally, we reviewed the potential obstacles in ACE-Is repurposing process. Results The alternation of angiotensin receptor expression in ovarian cancer translates into poorer patient survival. This confirms the participation of the renin-angiotensin system in ovarian carcinogenesis. In observational studies, ACE-Is were shown synergize with both, platinum-based chemotherapy as well as with antiangiogenic therapy. Consistently, our in silico simulation showed that ACE-Is are probably cytotoxic against ovarian cancer cells. However, the publications on their chemopreventive properties were inconclusive. In addition, some reports correlated ACE-Is use with increased general cancer incidence. We hypothesized that this effect could be associated with mutagenic nitrosamine formation in ACE-Is’ pharmaceutical formulations, as was the case with angiotensin receptor blockers (ARBs) and other well-established pharmaceuticals. Conclusions Available data warrant further research into repositioning ACE-Is to ovarian cancer as chemosensitizers. Prior to this, however, a special research program is needed to detect possible genotoxic contaminants of ACE-Is.

show abstract

“…What’s more, the rate of OC is steadily increasing, and recent data indicate a mortality-to-incidence ratio of 0.6 [ 5 , 6 ], reflecting a dramatic diagnostic delay [ 7 ]. Although early stage OC is highly curable, 4/5 women present with advanced disease [ 8 , 9 , 10 ], after the cancer has leaked from the pelvic cavity [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Marrelli

Ansaloni²,

Federici

et al. 2022

Cancers

View full text Add to dashboard Cite

Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.

show abstract

The world ovarian cancer coalition every woman study: Identifying global and local challenges, and the opportunities to improve survival and quality of life for women no matter where they live

Cited by 4 publications

References 0 publications

Untitled

Untitled

Angiotensin-converting enzyme inhibitors for ovarian cancer? — a new adjuvant option or a silent trap

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Contact Info

Product

Resources

About